Our results reveal that, in a pharmacological model induced by 3-NP treatment, which simulates earlier stages of Huntington’s disease (HD), Cdk5 may play a role in attenuating signaling pathways, influencing neurons to enhance their activity. This evidence concerns the gene CDK5 and Huntington disease.